1,5-anhydroglucitol Blood Test More Accurate than HbA1c and Glucose for Predicting Mortality COVID-19 Patients with and without Diabetes

  • Nov 2021

This week, Precision Diabetes, Inc. presented data demonstrating that the 1,5-anhydroglucitol blood test (GlycoMark®) is more accurate than commonly used diabetes tests in predicting mortality in hospitalized COVID-19 patients with and without diabetes. The study, “1,5-anhydroglucitol is an Independent Predictor of Mortality in Patients with COVID-19,” was presented at the American Heart Association (AHA) 2021 Scientific Sessions conference.

The study, conducted at Sinai Hospital in Baltimore, Md., showed that the GlycoMark® test had 76% mortality accuracy (AUC) compared to the accuracy for HbA1c and fasting glucose of 51% and 60%, respectively. The accuracy of GlycoMark was higher in patients without diabetes (79%) than in patients with diabetes (73%). An algorithm, which included age, BMI, and GlycoMark had an accuracy for prediction of mortality of 89%.

“We were pleased to find that the GlycoMark test identified mortality with high accuracy in COVID-19 patients,” says Paul Gurbel, MD, a cardiologist at the The LifeBridge Health Cardiovascular Institute and lead investigator of the trial. “GlycoMark may have utility in triaging COVID-19 patients in the hospital setting at higher risk of severity and mortality. This may be especially important in COVID-19 non-diabetic patients who may develop new-onset diabetes, which brings higher risks of severe disease and death.”

This study follows a previously reported study presented as a late-breaking abstract at the 2021 American Diabetes Association (ADA) Scientific Sessions, which showed that GlycoMark was an effective marker of stress hyperglycemia and severity in COVID-19 patients, particularly in patients without diabetes. The study was conducted at Hospital Universitario Cruces in Bilbao, Spain.

You may also like

  • Hyperinsulinemia Emerges as Critical Predictor of Severe Liver Outcomes

    By Jackie Oberst

    Researchers have identified fasting hyperinsulinemia as a primary, yet often overlooked, driver of metabolic dysfunction-associated steatotic liver disease (MASLD). A new review published in Hepatology suggests that elevated insulin levels are not merely a symptom of metabolic syndrome but a direct contributor to liver fibrosis and a potent predictor of major adverse liver and cardiovascular…

  • Father’s Tobacco Use May Raise Children’s Diabetes Risk

    By Jenni Glenn Gingery

    A mouse study found that a father’s nicotine exposure can affect the offspring’s ability to process sugar and may contribute to diabetes risk, according to new research published in the Journal of the Endocrine Society. An estimated 40.1 million people in the United States have diabetes, according to the U.S. Centers for Disease Control and Prevention. Having diabetes…

Find more in